Regulatory polymorphisms underlying complex disease traits.
PDF (653K)
Journal: 2005/June - Journal of Molecular Medicine
ISSN: 0946-2716
Abstract:
There is growing evidence that genetic variation plays an important role in the determination of individual susceptibility to complex disease traits. In contrast to coding sequence polymorphisms, where the consequences of non-synonymous variation may be resolved at the level of the protein phenotype, defining specific functional regulatory polymorphisms has proved problematic. This has arisen for a number of reasons, including difficulties with fine mapping due to linkage disequilibrium, together with a paucity of experimental tools to resolve the effects of non-coding sequence variation on gene expression. Recent studies have shown that variation in gene expression is heritable and can be mapped as a quantitative trait. Allele-specific effects on gene expression appear relatively common, typically of modest magnitude and context specific. The role of regulatory polymorphisms in determining susceptibility to a number of complex disease traits is discussed, including variation at the VNTR of INS, encoding insulin, in type 1 diabetes and polymorphism of CTLA4, encoding cytotoxic T lymphocyte antigen, in autoimmune disease. Examples where regulatory polymorphisms have been found to play a role in mongenic traits such as factor VII deficiency are discussed, and contrasted with those polymorphisms associated with ischaemic heart disease at the same gene locus. Molecular mechanisms operating in an allele-specific manner at the level of transcription are illustrated, with examples including the role of Duffy binding protein in malaria. The difficulty of resolving specific functional regulatory variants arising from linkage disequilibrium is demonstrated using a number of examples including polymorphism of CCR5, encoding CC chemokine receptor 5, and HIV-1 infection. The importance of understanding haplotypic structure to the design and interpretation of functional assays of putative regulatory variation is highlighted, together with discussion of the strategic use of experimental tools to resolve regulatory polymorphisms at a transcriptional level. A number of examples are discussed including work on the TNF locus which demonstrate biological and experimental context specificity. Regulatory variation may also operate at other levels of control of gene expression and the modulation of splicing at PTPRC, encoding protein tyrosine phosphatase receptor-type C, and of translational efficiency at F12, encoding factor XII, are discussed.
Open in
PUBMED | DOI | PMC | Google Scholar | Wikipedia
Relations:
Content
Citations
(73)
References
(125)
Diseases
(2)
Conditions
(1)
Drugs
(1)
Chemicals
(1)
Organisms
(1)
Processes
(3)
Affiliates
(1)
Similar articles
Articles by the same authors
Discussion board
J Mol Med (Berl) 83(2): 97-109
PMID: 15592805

Regulatory polymorphisms underlying complex disease traits

Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK, ku.ca.xo.llew@nailuj Tel.: +44-1865-287671, Fax: +44-1865-287533
Corresponding author.
Copyright notice

Abstract

There is growing evidence that genetic variation plays an important role in the determination of individual susceptibility to complex disease traits. In contrast to coding sequence polymorphisms, where the consequences of non-synonymous variation may be resolved at the level of the protein phenotype, defining specific functional regulatory polymorphisms has proved problematic. This has arisen for a number of reasons, including difficulties with fine mapping due to linkage disequilibrium, together with a paucity of experimental tools to resolve the effects of non-coding sequence variation on gene expression. Recent studies have shown that variation in gene expression is heritable and can be mapped as a quantitative trait. Allele-specific effects on gene expression appear relatively common, typically of modest magnitude and context specific. The role of regulatory polymorphisms in determining susceptibility to a number of complex disease traits is discussed, including variation at the VNTR of INS, encoding insulin, in type 1 diabetes and polymorphism of CTLA4, encoding cytotoxic T lymphocyte antigen, in autoimmune disease. Examples where regulatory polymorphisms have been found to play a role in mongenic traits such as factor VII deficiency are discussed, and contrasted with those polymorphisms associated with ischaemic heart disease at the same gene locus. Molecular mechanisms operating in an allele-specific manner at the level of transcription are illustrated, with examples including the role of Duffy binding protein in malaria. The difficulty of resolving specific functional regulatory variants arising from linkage disequilibrium is demonstrated using a number of examples including polymorphism of CCR5, encoding CC chemokine receptor 5, and HIV-1 infection. The importance of understanding haplotypic structure to the design and interpretation of functional assays of putative regulatory variation is highlighted, together with discussion of the strategic use of experimental tools to resolve regulatory polymorphisms at a transcriptional level. A number of examples are discussed including work on the TNF locus which demonstrate biological and experimental context specificity. Regulatory variation may also operate at other levels of control of gene expression and the modulation of splicing at PTPRC, encoding protein tyrosine phosphatase receptor-type C, and of translational efficiency at F12, encoding factor XII, are discussed.

Keywords: Gene expression, Genetics, Gene polymorphism, Promoter, Transcription
Abstract

Abbreviations

HIVHuman immunodeficiency virus
HNFHepatic nuclear factor
NFNuclear factor
SNPSingle nucleotide polymorphism
TNFTumour necrosis factor
UTRUntranslated region
VNTRVariable number tandem repeat
Abbreviations

Footnotes

The original publication is available at springerlink.com

Footnotes

References

  • 1. Glazier AM, Nadeau JH, Aitman TJFinding genes that underlie complex traits. Science. 2002;298:2345–2349.[PubMed][Google Scholar]
  • 2. Risch N, Merikangas KThe future of genetic studies of complex human diseases. Science. 1996;273:1516–1517.[PubMed][Google Scholar]
  • 3. Carlson CS, Eberle MA, Kruglyak L, Nickerson DAMapping complex disease loci in whole-genome association studies. Nature. 2004;429:446–452.[PubMed][Google Scholar]
  • 4. Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane CR, Lim EP, Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley GQ, Lander ESCharacterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet. 1999;22:231–238.[PubMed][Google Scholar]
  • 5. King MC, Wilson ACEvolution at two levels in humans and chimpanzees. Science. 1975;188:107–116.[PubMed][Google Scholar]
  • 6. Wray GA, Hahn MW, Abouheif E, Balhoff JP, Pizer M, Rockman MV, Romano LAThe evolution of transcriptional regulation in eukaryotes. Mol Biol Evol. 2003;20:1377–1419.[PubMed][Google Scholar]
  • 7. Schadt EE, Monks SA, Drake TA, Lusis AJ, Che N, Colinayo V, Ruff TG, Milligan SB, Lamb JR, Cavet G, Linsley PS, Mao M, Stoughton RB, Friend SHGenetics of gene expression surveyed in maize, mouse and man. Nature. 2003;422:297–302.[PubMed][Google Scholar]
  • 8. Yvert G, Brem RB, Whittle J, Akey JM, Foss E, Smith EN, Mackelprang R, Kruglyak LTransacting regulatory variation in Saccharomyces cerevisiae and the role of transcription factors. Nat Genet. 2003;35:57–64.[PubMed][Google Scholar]
  • 9. Brem RB, Yvert G, Clinton R, Kruglyak LGenetic dissection of transcriptional regulation in budding yeast. Science. 2002;296:752–755.[PubMed][Google Scholar]
  • 10. Townsend JP, Cavalieri D, Hartl DLPopulation genetic variation in genome-wide gene expression. Mol Biol Evol. 2003;20:955–963.[PubMed][Google Scholar]
  • 11. Fay JC, McCullough HL, Sniegowski PD, Eisen MBPopulation genetic variation in gene expression is associated with phenotypic variation in Saccharomyces cerevisiae. Genome Biol. 2004;5:R26.[Google Scholar]
  • 12. Rifkin SA, Kim J, White KPEvolution of gene expression in the Drosophila melanogaster subgroup. Nat Genet. 2003;33:138–144.[PubMed][Google Scholar]
  • 13. Oleksiak MF, Churchill GA, Crawford DLVariation in gene expression within and among natural populations. Nat Genet. 2002;32:261–266.[PubMed][Google Scholar]
  • 14. Enard W, Khaitovich P, Klose J, Zollner S, Heissig F, Giavalisco P, Nieselt-Struwe K, Muchmore E, Varki A, Ravid R, Doxiadis GM, Bontrop RE, Paabo SIntra- and inter-specific variation in primate gene expression patterns. Science. 2002;296:340–343.[PubMed][Google Scholar]
  • 15. Cheung VG, Conlin LK, Weber TM, Arcaro M, Jen KY, Morley M, Spielman RSNatural variation in human gene expression assessed in lymphoblastoid cells. Nat Genet. 2003;33:422–425.[PubMed][Google Scholar]
  • 16. Morley M, Molony CM, Weber TM, Devlin JL, Ewens KG, Spielman RS, Cheung VGGenetic analysis of genome-wide variation in human gene expression. Nature. 2004;430:743–747.[Google Scholar]
  • 17. Knight JCAllele-specific gene expression uncovered. Trends Genet. 2004;20:113–116.[PubMed][Google Scholar]
  • 18. Yan H, Yuan W, Velculescu VE, Vogelstein B, Kinzler KWAllelic variation in human gene expression. Science. 2002;297:1143.[PubMed][Google Scholar]
  • 19. Pastinen T, Sladek R, Gurd S, Sammak A, Ge B, Lepage P, Lavergne K, Villeneuve A, Gaudin T, Brandstrom H, Beck A, Verner A, Kingsley J, Harmsen E, Labuda D, Morgan K, Vohl MC, Naumova AK, Sinnett D, Hudson TJA survey of genetic and epigenetic variation affecting human gene expression. Physiol Genomics. 2004;16:184–193.[PubMed][Google Scholar]
  • 20. Cowles CR, Hirschhorn JN, Altshuler D, Lander ESDetection of regulatory variation in mouse genes. Nat Genet. 2002;32:432–437.[PubMed][Google Scholar]
  • 21. Bray NJ, Buckland PR, Owen MJ, O'Donovan MCCis-acting variation in the expression of a high proportion of genes in human brain. Hum Genet. 2003;113:149–153.[PubMed][Google Scholar]
  • 22. Alam J, Cook JLReporter genes: application to the study of mammalian gene transcription. Anal Biochem. 1990;188:245–254.[PubMed][Google Scholar]
  • 23. Rockman MV, Wray GAAbundant raw material for cis-regulatory evolution in humans. Mol Biol Evol. 2002;19:1991–2004.[PubMed][Google Scholar]
  • 24. Hoogendoorn B, Coleman SL, Guy CA, Smith K, Bowen T, Buckland PR, O'Donovan MCFunctional analysis of human promoter polymorphisms. Hum Mol Genet. 2003;12:2249–2254.[PubMed][Google Scholar]
  • 25. Buckland PR, Coleman SL, Hoogendoorn B, Guy C, Smith SK, O'Donovan MCA high proportion of chromosome 21 promoter polymorphisms influence transcriptional activity. Gene Expr. 2004;11:233–239.[Google Scholar]
  • 26. Hoogendoorn B, Coleman SL, Guy CA, Smith SK, O'Donovan MC, Buckland PRFunctional analysis of polymorphisms in the promoter regions of genes on 22q11. Hum Mutat. 2004;24:35–42.[PubMed][Google Scholar]
  • 27. Banerjee P, Bahlo M, Schwartz JR, Loots GG, Houston KA, Dubchak I, Speed TP, Rubin EMSNPs in putative regulatory regions identified by human mouse comparative sequencing and transcription factor binding site data. Mamm Genome. 2002;13:554–557.[PubMed][Google Scholar]
  • 28. Bulyk MLComputational prediction of transcription-factor binding site locations. Genome Biol. 2003;5:201.[Google Scholar]
  • 29. Linnell J, Mott R, Field S, Kwiatkowski DP, Ragoussis J, Udalova IAQuantitative high-throughput analysis of transcription factor binding specificities. Nucleic Acids Res. 2004;32:e44.[Google Scholar]
  • 30. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, Rainbow DB, Hunter KM, Smith AN, Di Genova G, Herr MH, Dahlman I, Payne F, Smyth D, Lowe C, Twells RC, Howlett S, Healy B, Nutland S, Rance HE, Everett V, Smink LJ, Lam AC, Cordell HJ, Walker NM, Bordin C, Hulme J, Motzo C, Cucca F, Hess JF, Metzker ML, Rogers J, Gregory S, Allahabadia A, Nithiyananthan R, Tuomilehto-Wolf E, Tuomilehto J, Bingley P, Gillespie KM, Undlien DE, Ronningen KS, Guja C, Ionescu-Tirgoviste C, Savage DA, Maxwell AP, Carson DJ, Patterson CC, Franklyn JA, Clayton DG, Peterson LB, Wicker LS, Todd JA, Gough SCAssociation of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature. 2003;423:506–511.[PubMed][Google Scholar]
  • 31. Tournamille C, Colin Y, Cartron JP, Le Van Kim CDisruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals. Nat Genet. 1995;10:224–228.[PubMed][Google Scholar]
  • 32. Kennedy GC, German MS, Rutter WJThe minisatellite in the diabetes susceptibility locus IDDM 2 regulates insulin transcription. Nat Genet. 1995;9:293–298.[PubMed][Google Scholar]
  • 33. Bell GI, Selby MJ, Rutter WJThe highly polymorphic region near the human insulin gene is composed of simple tandemly repeating sequences. Nature. 1982;295:31–35.[PubMed][Google Scholar]
  • 34. Bell GI, Horita S, Karam JHA polymorphic locus near the human insulin gene is associated with insulin-dependent diabetes mellitus. Diabetes. 1984;33:176–183.[PubMed][Google Scholar]
  • 35. Hitman GA, Tarn AC, Winter RM, Drummond V, Williams LG, Jowett NI, Bottazzo GF, Galton DJType 1 (insulin-dependent) diabetes and a highly variable locus close to the insulin gene on chromosome 11. Diabetologia. 1985;28:218–222.[PubMed][Google Scholar]
  • 36. Lucassen AM, Julier C, Beressi JP, Boitard C, Froguel P, Lathrop M, Bell JISusceptibility to insulin dependent diabetes mellitus maps to a 4.1 kb segment of DNA spanning the insulin gene and associated VNTR. Nat Genet. 1993;4:305–310.[PubMed][Google Scholar]
  • 37. Bennett ST, Lucassen AM, Gough SC, Powell EE, Undlien DE, Pritchard LE, Merriman ME, Kawaguchi Y, Dronsfield MJ, Pociot F, et al Susceptibility to human type 1 diabetes at IDDM 2 is determined by tandem repeat variation at the insulin gene minisatellite locus. Nat Genet. 1995;9:284–292.[PubMed][Google Scholar]
  • 38. Barratt BJ, Payne F, Lowe CE, Hermann R, Healy BC, Harold D, Concannon P, Gharani N, McCarthy MI, Olavesen MG, McCormack R, Guja C, Ionescu-Tirgoviste C, Undlien DE, Ronningen KS, Gillespie KM, Tuomilehto-Wolf E, Tuomilehto J, Bennett ST, Clayton DG, Cordell HJ, Todd JARemapping the insulin gene/IDDM 2 locus in type 1 diabetes. Diabetes. 2004;53:1884–1889.[PubMed][Google Scholar]
  • 39. Pugliese A, Awdeh ZL, Alper CA, Jackson RA, Eisenbarth GSThe paternally inherited insulin gene B allele (1,428 FokI site) confers protection from insulin-dependent diabetes in families. J Autoimmunol. 1994;7:687–694.[PubMed][Google Scholar]
  • 40. Bennett ST, Wilson AJ, Cucca F, Nerup J, Pociot F, McKinney PA, Barnett AH, Bain SC, Todd JAIDDM 2-VNTR-encoded susceptibility to type 1 diabetes: dominant protection and parental transmission of alleles of the insulin gene-linked minisatellite locus. J Autoimmunol. 1996;9:415–421.[PubMed][Google Scholar]
  • 41. Florez JC, Hirschhorn J, Altshuler DThe inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits. Annu Rev Genomics Hum Genet. 2003;4:257–291.[PubMed][Google Scholar]
  • 42. Vafiadis P, Bennett ST, Colle E, Grabs R, Goodyer CG, Polychronakos CImprinted and genotype-specific expression of genes at the IDDM 2 locus in pancreas and leucocytes. J Autoimmunol. 1996;9:397–403.[PubMed][Google Scholar]
  • 43. Weaver JU, Kopelman PG, Hitman GACentral obesity and hyperinsulinaemia in women are associated with polymorphism in the 5′ flanking region of the human insulin gene. Eur J Clin Invest. 1992;22:265–270.[PubMed][Google Scholar]
  • 44. Cocozza S, Riccardi G, Monticelli A, Capaldo B, Genovese S, Krogh V, Celentano E, Farinaro E, Varrone S, Avvedimento VEPolymorphism at the 5′ end flanking region of the insulin gene is associated with reduced insulin secretion in healthy individuals. Eur J Clin Invest. 1988;18:582–586.[PubMed][Google Scholar]
  • 45. Permutt MA, Rotwein P, Andreone T, Ward WK, Porte D., Jr Islet beta-cell function and polymorphism in the 5′flanking region of the human insulin gene. Diabetes. 1985;34:311–314.[PubMed]
  • 46. Owerbach D, Poulsen S, Billesbolle P, Nerup JDNA insertion sequences near the insulin gene affect glucose regulation. Lancet. 1982;I:880–883.[PubMed][Google Scholar]
  • 47. Lucassen AM, Screaton GR, Julier C, Elliott TJ, Lathrop M, Bell JIRegulation of insulin gene expression by the IDDM associated, insulin locus haplotype. Hum Mol Genet. 1995;4:501–506.[PubMed][Google Scholar]
  • 48. Catasti P, Chen X, Moyzis RK, Bradbury EM, Gupta GStructure-function correlations of the insulin-linked polymorphic region. J Mol Biol. 1996;264:534–545.[PubMed][Google Scholar]
  • 49. Lew A, Rutter WJ, Kennedy GCUnusual DNA structure of the diabetes susceptibility locus IDDM 2 and its effect on transcription by the insulin promoter factor Pur-1/MAZ. Proc Natl Acad Sci U S A. 2000;97:12508–12512.[Google Scholar]
  • 50. Pugliese A, Zeller M, Fernandez A, Jr, Zalcberg LJ, Bartlett RJ, Ricordi C, Pietropaolo M, Eisenbarth GS, Bennett ST, Patel DDThe insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM 2 susceptibility locus for type 1 diabetes. Nat Genet. 1997;15:293–297.[PubMed][Google Scholar]
  • 51. Vafiadis P, Bennett ST, Todd JA, Nadeau J, Grabs R, Goodyer CG, Wickramasinghe S, Colle E, Polychronakos CInsulin expression in human thymus is modulated by INS VNTR alleles at the IDDM 2 locus. Nat Genet. 1997;15:289–292.[PubMed][Google Scholar]
  • 52. Paquette J, Giannoukakis N, Polychronakos C, Vafiadis P, Deal CThe INS 5′ variable number of tandem repeats is associated with IGF2 expression in humans. J Biol Chem. 1998;273:14158–14164.[PubMed][Google Scholar]
  • 53. Vafiadis P, Grabs R, Goodyer CG, Colle E, Polychronakos CA functional analysis of the role of IGF2 in IDDM 2-encoded susceptibility to type 1 diabetes. Diabetes. 1998;47:831–836.[PubMed][Google Scholar]
  • 54. Cooke GS, Hill AVGenetics of susceptibility to human infectious disease. Nat Rev Genet. 2001;2:967–977.[PubMed][Google Scholar]
  • 55. Theodorou I, Capoulade C, Combadiere C, Debre PGenetic control of HIV disease. Trends Microbiol. 2003;11:392–397.[PubMed][Google Scholar]
  • 56. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C, Muyldermans G, Verhofstede C, Burtonboy G, Georges M, Imai T, Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G, Parmentier MResistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 1996;382:722–725.[PubMed][Google Scholar]
  • 57. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T, Kang S, Ceradini D, Jin Z, Yazdanbakhsh K, Kunstman K, Erickson D, Dragon E, Landau NR, Phair J, Ho DD, Koup RAThe role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med. 1996;2:1240–1243.[PubMed][Google Scholar]
  • 58. Anastassopoulou CG, Kostrikis LGThe impact of human allelic variation on HIV-1 disease. Curr HIV Res. 2003;1:185–203.[PubMed][Google Scholar]
  • 59. Martin MP, Dean M, Smith MW, Winkler C, Gerrard B, Michael NL, Lee B, Doms RW, Margolick J, Buchbinder S, Goedert JJ, O'Brien TR, Hilgartner MW, Vlahov D, O'Brien SJ, Carrington MGenetic acceleration of AIDS progression by a promoter variant of CCR5. Science. 1998;282:1907–1911.[PubMed][Google Scholar]
  • 60. McDermott DH, Zimmerman PA, Guignard F, Kleeberger CA, Leitman SF, Murphy PM. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS) Lancet. 1998;352:866–870.[PubMed]
  • 61. Mummidi S, Ahuja SS, Gonzalez E, Anderson SA, Santiago EN, Stephan KT, Craig FE, O'Connell P, Tryon V, Clark RA, Dolan MJ, Ahuja SKGenealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat Med. 1998;4:786–793.[PubMed][Google Scholar]
  • 62. Clegg AO, Ashton LJ, Biti RA, Badhwar P, Williamson P, Kaldor JM, Stewart GJ. CCR5 promoter polymorphisms, CCR5 59029A and CCR5 59353C, are under represented in HIV-1-infected long-term non-progressors. The Australian Long-Term Non-Progressor Study Group. AIDS. 2000;14:103–108.[PubMed]
  • 63. Knudsen TB, Kristiansen TB, Katzenstein TL, Eugen-Olsen JAdverse effect of the CCR5 promoter −2459A allele on HIV-1 disease progression. J Med Virol. 2001;65:441–444.[PubMed][Google Scholar]
  • 64. Mummidi S, Bamshad M, Ahuja SS, Gonzalez E, Feuillet PM, Begum K, Galvis MC, Kostecki V, Valente AJ, Murthy KK, Haro L, Dolan MJ, Allan JS, Ahuja SK. Evolution of human and non-human primate CC chemokine receptor 5 gene and mRNA. Potential roles for haplotype and mRNA diversity, differential haplotype-specific transcriptional activity, and altered transcription factor binding to polymorphic nucleotides in the pathogenesis of HIV-1 and simian immunodeficiency virus. J Biol Chem. 2000;275:18946–18961.[PubMed]
  • 65. Salkowitz JR, Bruse SE, Meyerson H, Valdez H, Mosier DE, Harding CV, Zimmerman PA, Lederman MMCCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro. Clin Immunol. 2003;108:234–240.[Google Scholar]
  • 66. Kawamura T, Gulden FO, Sugaya M, McNamara DT, Borris DL, Lederman MM, Orenstein JM, Zimmerman PA, Blauvelt AR5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms. Proc Natl Acad Sci U S A. 2003;100:8401–8406.[Google Scholar]
  • 67. Bream JH, Young HA, Rice N, Martin MP, Smith MW, Carrington M, O'Brien SJCCR5 promoter alleles and specific DNA binding factors. Science. 1999;284:223.[PubMed][Google Scholar]
  • 68. Jepson A, Sisay-Joof F, Banya W, Hassan-King M, Frodsham A, Bennett S, Hill AVS, Whittle HGenetic linkage of mild malaria to the major histocompatibility complex in Gambian children: study of affected sibling pairs. BMJ. 1997;315:96–97.[Google Scholar]
  • 69. Flori L, Sawadogo S, Esnault C, Delahaye NF, Fumoux F, Rihet PLinkage of mild malaria to the major histocompatibility complex in families living in Burkina Faso. Hum Mol Genet. 2003;12:375–378.[PubMed][Google Scholar]
  • 70. McGuire W, Hill AVS, Allsopp CEM, Greenwood BM, Kwiatkowski DVariation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature. 1994;371:508–511.[PubMed][Google Scholar]
  • 71. Wattavidanage J, Carter R, Perera KL, Munasingha A, Bandara S, McGuinness D, Wickramasinghe AR, Alles HK, Mendis KN, Premawansa STNFalpha*2 marks high risk of severe disease during Plasmodium falciparum malaria and other infections in Sri Lankans. Clin Exp Immunol. 1999;115:350–355.[Google Scholar]
  • 72. Padyukov L, Lampa J, Heimburger M, Ernestam S, Cederholm T, Lundkvist I, Andersson P, Hermansson Y, Harju A, Klareskog L, Bratt JGenetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis. 2003;62:526–529.[Google Scholar]
  • 73. Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron DPolymorphism at position −308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum. 2003;48:1849–1852.[PubMed][Google Scholar]
  • 74. Allen RDPolymorphism of the human TNF-alpha promoter-random variation or functional diversity? Mol Immunol. 1999;36:1017–1027.[PubMed][Google Scholar]
  • 75. Bayley JP, Ottenhoff TH, Verweij CLIs there a future for TNF promoter polymorphisms? Genes Immunol. 2004;5:315–329.[PubMed][Google Scholar]
  • 76. Kroeger KM, Steer JH, Joyce DA, Abraham LJEffects of stimulus and cell type on the expression of the −308 tumour necrosis factor promoter polymorphism. Cytokine. 2000;12:110–119.[PubMed][Google Scholar]
  • 77. Kroeger KM, Carville KS, Abraham LJThe −308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol. 1997;34:391–399.[PubMed][Google Scholar]
  • 78. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GWEffects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA. 1997;94:3195–3199.[Google Scholar]
  • 79. Knight JC, Udalova I, Hill AV, Greenwood BM, Peshu N, Marsh K, Kwiatkowski DA polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria. Nat Genet. 1999;22:145–150.[PubMed][Google Scholar]
  • 80. Knight JC, Keating BJ, Rockett KA, Kwiatkowski DPIn vivo characterization of regulatory polymorphisms by allele-specific quantification of RNA polymerase loading. Nat Genet. 2003;33:469–475.[PubMed][Google Scholar]
  • 81. Ozaki K, Ohnishi Y, Iida A, Sekine A, Yamada R, Tsunoda T, Sato H, Hori M, Nakamura Y, Tanaka TFunctional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet. 2002;32:650–654.[PubMed][Google Scholar]
  • 82. Newton J, Brown MA, Milicic A, Ackerman H, Darke C, Wilson JN, Wordsworth BP, Kwiatkowski DThe effect of HLA-DR on susceptibility to rheumatoid arthritis is influenced by the associated lymphotoxin alpha-tumor necrosis factor haplotype. Arthritis Rheum. 2003;48:90–96.[PubMed][Google Scholar]
  • 83. Knight JC, Keating BJ, Kwiatkowski DPAllele-specific repression of lymphotoxin-alpha by activated B cell factor-1. Nat Genet. 2004;36:394–399.[PubMed][Google Scholar]
  • 84. McGuire W, Knight JC, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski DSevere malarial anemia and cerebral malaria are associated with different tumor necrosis factor promoter alleles. J Infect Dis. 1999;179:287–290.[PubMed][Google Scholar]
  • 85. Mombo LE, Ntoumi F, Bisseye C, Ossari S, Lu CY, Nagel RL, Krishnamoorthy RHuman genetic polymorphisms and asymptomatic Plasmodium falciparum malaria in Gabonese schoolchildren. Am J Trop Med Hyg. 2003;68:186–190.[PubMed][Google Scholar]
  • 86. Fong CL, Siddiqui AH, Mark DFIdentification and characterization of a novel repressor site in the human tumor necrosis factor alpha gene. Nucleic Acids Res. 1994;22:1108–1114.[Google Scholar]
  • 87. Fabris M, Di PE, D'Elia A, Damante G, Sinigaglia L, Ferraccioli GTumor necrosis factor-alpha gene polymorphism in severe and mild-moderate rheumatoid arthritis. J Rheumatol. 2002;29:29–33.[PubMed][Google Scholar]
  • 88. Brinkman BM, Huizinga TW, Kurban SS, van der Velde EA, Schreuder GM, Hazes JM, Breedveld FC, Verweij CLTumour necrosis factor alpha gene polymorphisms in rheumatoid arthritis: association with susceptibility to, or severity of, disease? Br J Rheumatol. 1997;36:516–521.[PubMed][Google Scholar]
  • 89. Perry DJFactor VII Deficiency. Br J Haematol. 2002;118:689–700.[PubMed][Google Scholar]
  • 90. Arbini AA, Pollak ES, Bayleran JK, High KA, Bauer KASevere factor VII deficiency due to a mutation disrupting a hepatocyte nuclear factor 4 binding site in the factor VII promoter. Blood. 1997;89:176–182.[PubMed][Google Scholar]
  • 91. Pollak ES, Hung HL, Godin W, Overton GC, High KAFunctional characterization of the human factor VII 5′-flanking region. J Biol Chem. 1996;271:1738–1747.[PubMed][Google Scholar]
  • 92. Carew JA, Pollak ES, Lopaciuk S, Bauer KAA new mutation in the HNF4 binding region of the factor VII promoter in a patient with severe factor VII deficiency. Blood. 2000;96:4370–4372.[PubMed][Google Scholar]
  • 93. Carew JA, Pollak ES, High KA, Bauer KASevere factor VII deficiency due to a mutation disrupting an Sp1 binding site in the factor VII promoter. Blood. 1998;92:1639–1645.[PubMed][Google Scholar]
  • 94. Greenberg D, Miao CH, Ho WT, Chung DW, Davie EWLiver-specific expression of the human factor VII gene. Proc Natl Acad Sci USA. 1995;92:12347–12351.[Google Scholar]
  • 95. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Thompson SGHaemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986;II:533–537.[PubMed][Google Scholar]
  • 96. Bernardi F, Marchetti G, Pinotti M, Arcieri P, Baroncini C, Papacchini M, Zepponi E, Ursicino N, Chiarotti F, Mariani GFactor VII gene polymorphisms contribute about one third of the factor VII level variation in plasma. Arterioscler Thromb Vasc Biol. 1996;16:72–76.[PubMed][Google Scholar]
  • 97. Green F, Kelleher C, Wilkes H, Temple A, Meade T, Humphries SA common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscler Thromb. 1991;11:540–546.[PubMed][Google Scholar]
  • 98. Iacoviello L, Di Castelnuovo A, De Knijff P, D'Orazio A, Amore C, Arboretti R, Kluft C, Benedetta Donati MPolymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med. 1998;338:79–85.[PubMed][Google Scholar]
  • 99. Girelli D, Russo C, Ferraresi P, Olivieri O, Pinotti M, Friso S, Manzato F, Mazzucco A, Bernardi F, Corrocher RPolymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. N Engl J Med. 2000;343:774–780.[PubMed][Google Scholar]
  • 100. Doggen CJ, Manger Cats V, Bertina RM, Reitsma PH, Vandenbroucke JP, Rosendaal FRA genetic propensity to high factor VII is not associated with the risk of myocardial infarction in men. Thromb Haemost. 1998;80:281–285.[PubMed][Google Scholar]
  • 101. Batalla A, Alvarez R, Reguero JR, Gonzalez P, Alvarez V, Cubero GI, Cortina A, Coto ELack of association between polymorphisms of the coagulation factor VII and myocardial infarction in middle-aged Spanish men. Int J Cardiol. 2001;80:209–212.[PubMed][Google Scholar]
  • 102. Carew JA, Basso F, Miller GJ, Hawe E, Jackson AA, Humphries SE, Bauer KAA functional haplotype in the 5′ flanking region of the factor VII gene is associated with an increased risk of coronary heart disease. J Thromb Haemost. 2003;1:2179–2185.[PubMed][Google Scholar]
  • 103. Di Castelnuovo A, D'Orazio A, Amore C, Falanga A, Donati MB, Iacoviello LThe decanucleotide insertion/deletion polymorphism in the promoter region of the coagulation factor VII gene and the risk of familial myocardial infarction. Thromb Res. 2000;98:9–17.[PubMed][Google Scholar]
  • 104. Humphries S, Temple A, Lane A, Green F, Cooper J, Miller GLow plasma levels of factor VIIc and antigen are more strongly associated with the 10 base pair promoter (−323) insertion than the glutamine 353 variant. Thromb Haemost. 1996;75:567–572.[PubMed][Google Scholar]
  • 105. Hunault M, Arbini AA, Lopaciuk S, Carew JA, Bauer KA. The Arg353Gln polymorphism reduces the level of coagulation factor VII. In vivo and in vitro studies. Arterioscler Thromb Vasc Biol. 1997;17:2825–2829.[PubMed]
  • 106. Kudaravalli R, Tidd T, Pinotti M, Ratti A, Santacroce R, Margaglione M, Dallapiccola B, Bernardi F, Fortina P, Devoto M, Pollak ESPolymorphic changes in the 5′ flanking region of factor VII have a combined effect on promoter strength. Thromb Haemost. 2002;88:763–767.[PubMed][Google Scholar]
  • 107. Hooft FM van 't, Silveira A, Tornvall P, Iliadou A, Ehrenborg E, Eriksson P, Hamsten ATwo common functional polymorphisms in the promoter region of the coagulation factor VII gene determining plasma factor VII activity and mass concentration. Blood. 1999;93:3432–3441.[PubMed][Google Scholar]
  • 108. Pinotti M, Toso R, Girelli D, Bindini D, Ferraresi P, Papa ML, Corrocher R, Marchetti G, Bernardi FModulation of factor VII levels by intron 7 polymorphisms: population and in vitro studies. Blood. 2000;95:3423–3428.[PubMed][Google Scholar]
  • 109. Miller LH, Mason SJ, Clyde DF, McGinniss MH. The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N Engl J Med. 1976;295:302–304.[PubMed]
  • 110. Horuk R, Chitnis CE, Darbonne WC, Colby TJ, Rybicki A, Hadley TJ, Miller LHA receptor for the malarial parasite Plasmodium vivax: the erythrocyte chemokine receptor. Science. 1993;261:1182–1184.[PubMed][Google Scholar]
  • 111. Hamblin MT, Di Rienzo ADetection of the signature of natural selection in humans: evidence from the Duffy blood group locus. Am J Hum Genet. 2000;66:1669–1679.[Google Scholar]
  • 112. Maniatis T, Reed RAn extensive network of coupling among gene expression machines. Nature. 2002;416:499–506.[PubMed][Google Scholar]
  • 113. Orphanides G, Reinberg DA unified theory of gene expression. Cell. 2002;108:439–451.[PubMed][Google Scholar]
  • 114. Pagani F, Baralle FEGenomic variants in exons and introns: identifying the splicing spoilers. Nat Rev Genet. 2004;5:389–396.[PubMed][Google Scholar]
  • 115. Lynch KW, Weiss AA CD45 polymorphism associated with multiple sclerosis disrupts an exonic splicing silencer. J Biol Chem. 2001;276:24341–24347.[PubMed][Google Scholar]
  • 116. Jacobsen M, Schweer D, Ziegler A, Gaber R, Schock S, Schwinzer R, Wonigeit K, Lindert RB, Kantarci O, Schaefer-Klein J, Schipper HI, Oertel WH, Heidenreich F, Weinshenker BG, Sommer N, Hemmer BA point mutation in PTPRC is associated with the development of multiple sclerosis. Nat Genet. 2000;26:495–499.[PubMed][Google Scholar]
  • 117. Barcellos LF, Caillier S, Dragone L, Elder M, Vittinghoff E, Bucher P, Lincoln RR, Pericak-Vance M, Haines JL, Weiss A, Hauser SL, Oksenberg JR. PTPRC (CD45) is not associated with the development of multiple sclerosis in U.S. patients. Nat Genet. 2001;29:23–24.[PubMed]
  • 118. Schwinzer R, Wonigeit K. Genetically determined lack of CD45R-T cells in healthy individuals. Evidence for a regulatory polymorphism of CD45R antigen expression. J Exp Med. 1990;171:1803–1808.
  • 119. Thude H, Hundrieser J, Wonigeit K, Schwinzer RA point mutation in the human CD45 gene associated with defective splicing of exon A. Eur J Immunol. 1995;25:2101–2106.[PubMed][Google Scholar]
  • 120. Zilch CF, Walker AM, Timon M, Goff LK, Wallace DL, Beverley PCA point mutation within CD45 exon A is the cause of variant CD45RA splicing in humans. Eur J Immunol. 1998;28:22–29.[PubMed][Google Scholar]
  • 121. Zito F, Lowe GD, Rumley A, McMahon AD, Humphries SEAssociation of the factor XII 46C>T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study. Atherosclerosis. 2002;165:153–158.[PubMed][Google Scholar]
  • 122. Tirado I, Manuel Soria J, Mateo J, Oliver A, Carlos Souto J, Santamaria A, Felices R, Borrell M, Fontcuberta JAssociation after linkage analysis indicates that homozygosity for the 46C->T polymorphism in the F12 gene is a genetic risk factor for venous thrombosis. Thromb Haemost. 2004;91:899–904.[PubMed][Google Scholar]
  • 123. Kanaji T, Okamura T, Osaki K, Kuroiwa M, Shimoda K, Hamasaki N, Niho YA common genetic polymorphism (46 C to T substitution) in the 5′-untranslated region of the coagulation factor XII gene is associated with low translation efficiency and decrease in plasma factor XII level. Blood. 1998;91:2010–2014.[PubMed][Google Scholar]
  • 124. Kohler HP, Futers TS, Grant PJFXII (46C->T) polymorphism and in vivo generation of FXII activity-gene frequencies and relationship in patients with coronary artery disease. Thromb Haemost. 1999;81:745–747.[PubMed][Google Scholar]
  • 125. Zito F, Drummond F, Bujac SR, Esnouf MP, Morrissey JH, Humphries SE, Miller GJEpidemiological and genetic associations of activated factor XII concentration with factor VII activity, fibrinopeptide A concentration, and risk of coronary heart disease in men. Circulation. 2000;102:2058–2062.[PubMed][Google Scholar]
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.